Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLYX

Polaryx Therapeutics Inc

Mar 11 • 09:47AM ET

5.61

-0.36 -5.98 %

Healthcare • Biotechnology • USA • NASD

Mar 10, 7:30 PMRetail momentum reignited prior CRO selection buzz amid low-float trading.

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	91.81%	Shs Outstand	47.34M	Perf Week	101.19%
Market Cap	265.73M	Forward P/E	-	EPS next Y	-	Insider Trans	0.01%	Shs Float	3.88M	Perf Month	-5.34%
Enterprise Value	259.98M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	5.60%	Perf Quarter	-
Income	-8.21M	P/S	-	EPS this Y	-	Inst Trans	42.92%	Short Ratio	0.06	Perf Half Y	-
Sales	0.00M	P/B	50.13	EPS next Y	-	ROA	-	Short Interest	0.22M	Perf YTD	-83.96%
Book/sh	0.11	P/C	46.21	EPS next 5Y	-	ROE	-	52W High	48.91 -88.52%	Perf Year	-
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-154.93%	52W Low	2.20 155.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	38.53% 29.44%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	2.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	22.19	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	8.77	EPS Q/Q	-85.28%	SMA20	74.61%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-15.37%	Rel Volume	1.69	Prev Close	5.97
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-15.37%	Avg Volume	3.39M	Price	5.61
IPO	Feb 02, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	523,034	Change	-5.98%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-26	Initiated	Maxim Group	Buy	$10

Feb-27-26 08:30AM	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders (GlobeNewswire)
Feb-17-26 10:26AM	Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
08:30AM	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)
Feb-10-26 08:30AM	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium (GlobeNewswire) -24.11%
Feb-05-26 08:30AM	Polaryx Therapeutics Welcomes New Members of the Board of Directors (GlobeNewswire) -28.89%
08:40AM	Loading…
Feb-04-26 08:40AM	Polaryx to present late-breaker data related to Soteria ahead of trial (TipRanks)
Feb-03-26 08:30AM	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch (GlobeNewswire) -37.29%
Feb-02-26 08:30AM	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" (GlobeNewswire)

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Landis G. Michael	Chief Financial Officer	Feb 18 '26	Buy	2.79	2,867	7,991	228,225	Feb 20 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLYX

Polaryx Therapeutics Inc

Upgrade your FINVIZ experience